Publications
92
Citations
559
Est. group size
~2
Recurring co-author estimate
Active years
36
Publishing since 1991
This researcher focuses on radiation oncology and its role in treating cancers such as non-small-cell lung cancer, sarcomas (including angiosarcoma and retroperitoneal sarcoma), and brain metastases. Work spans clinical trials of radiotherapy and drug combinations, population-based outcome studies, and reviews of treatment approaches like hypofractionated radiotherapy and antibody-drug conjugates. Much of the research is conducted through multicenter cooperative group trials and involves collaboration with oncology and surgery teams.
Publication output has remained fairly steady over the last decade, averaging about 5 papers per year with modest year-to-year fluctuation and no clear upward or downward trend.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Abstract 539: Cholesterol triggers chromatin stress to drive senescence and inflammation.
Cancer Research · 2026
- CCTG BR.38: Consolidative use of radiotherapy to block (CURB2) oligoprogression in patients with metastatic non–small-cell lung cancer—A randomized phase III trial.
Journal of Clinical Oncology · 2026
- Parkin deficiency promotes colorectal tumorigenesis and progression through RIPK3‐dependent necroptotic inflammation
Cancer Communications · 2025
- Abstract 4689: Poly ADP ribose polymerase inhibitors potentiate proton therapy end-of-range relative biological effective dose by increasing replication stress
Cancer Research · 2025
- 505 Treatment options for cardiac sarcoma? Insights from a population-based study
Radiotherapy and Oncology · 2025
- Comparisons of survival outcomes of antibody-drug-conjugates in metastatic breast cancer: A network meta-analysis.
Journal of Clinical Oncology · 2025
- Treatment-related toxicities of antibody-drug conjugates in breast cancer: A Bayesian network meta-analysis.
Journal of Clinical Oncology · 2025
- Alliance A091902: A multicenter randomized phase II trial of paclitaxel (P) with or without nivolumab (N) in patients (pts) with advanced angiosarcoma (AS).
Journal of Clinical Oncology · 2024
- Trial in Progress - Alliance A052101: A Randomized Phase 3 Trial of Continuous Vs. Intermittent Maintenance Therapy with Zanubrutinib As Upfront Treatment in Older Patients with Mantle Cell Lymphoma
Blood · 2024
- Outcomes of non‐angiosarcoma radiation‐associated soft tissue sarcomas of the chest
Journal of Surgical Oncology · 2024
- Accelerated Hypofractionated Radiotherapy for the Definitive Management of Locally Advanced Non-Small Cell Lung Cancer: A Systematic Review
International Journal of Radiation Oncology*Biology*Physics · 2024
- 133 Hypofractionated Radiotherapy for the Definitive Management of Locally Advanced Non-Small Cell Lung Cancer: A Systematic Review
Radiotherapy and Oncology · 2024
- Efficacy and treatment-related toxicities of antibody-drug conjugates in breast cancer
2024
- A multicenter phase II study of cabozantinib + nivolumab for patients (pts) with advanced angiosarcoma (AS) previously treated with a taxane (Alliance A091902).
Journal of Clinical Oncology · 2023
- EP07.02-03 High-Dose Rate Endobronchial Brachytherapy with Palliative and Definitive Intent at a Tertiary Care Hospital
Journal of Thoracic Oncology · 2023
- International Journal of Radiation Oncology*Biology*Physics×22
- Journal of Clinical Oncology×10
- Journal of Thoracic Oncology×6
- Radiotherapy and Oncology×3
- Blood×2
- A. Foster
Medicine · Indiana University
- Manny Coker‐Schwimmer
Medicine · The Ohio State University
- Robert E. Merritt
Medicine · The Ohio State University
- Wei Tang
Medicine · Indiana University
- Yuanyuan Zhang
Medicine · Purdue University West Lafayette
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile